Tracking the Pharmaceutical Pipeline: Clinical Trials and Global Disease Burden
- 9 May 2014
- journal article
- Published by Wiley in Clinical and Translational Science
- Vol. 7 (4), 297-299
- https://doi.org/10.1111/cts.12163
Abstract
Aggregate data about pharmaceutical research and development (R&D) tend to examine Phase III trials. Hence, there are few published data about investigational drugs in earlier phases of clinical development that might fail. It is also unclear how well R&D corresponds to disease burden. We track the pharmaceutical pipeline using data from industry publications that provide otherwise unreported information about industry-sponsored clinical trials. The sample includes 2,477 unique drug entities in 4,182 clinical trials. The majority of drugs targeted neoplasms (26.20%), neurological diseases/diseases of the sense organs (13.48%), infectious and parasitic diseases (10.5%), and endocrine, metabolic, nutrition, and immunity disorders (9.45%). Less than 6% of drugs targeted diseases of the circulatory system, which represent the most prevalent causes of global mortality. Detailing the pharmaceutical pipeline, our findings suggest that pharmaceutical development does not adequately address global disease burden. Future research on the under-reported details of Phase I and II clinical trials is needed to understand how the industry operates and how its resource-allocation matches global health concerns.Keywords
Funding Information
- U.S. National Institutes of Health, National Cancer Institute (5R21CA131880)
- Vanderbilt CTSA and the NIH National Center for Research Resources (1UL1RR024975)
This publication has 8 references indexed in Scilit:
- Clinical trial website struggles to serve as research data hubNature Medicine, 2012
- How Many “Me-Too” Drugs Is Too Many?JAMA, 2011
- Trends in Risks Associated With New Drug Development: Success Rates for Investigational DrugsClinical Pharmacology & Therapeutics, 2010
- Financing of U.S. Biomedical Research and New Drug Approvals across Therapeutic AreasPLOS ONE, 2009
- Relation between the Global Burden of Disease and Randomized Clinical Trials Conducted in Latin America Published in the Five Leading Medical JournalsPLOS ONE, 2008
- The Medicine Cabinet: What’s In It, Why, And Can We Change The Contents?Health Affairs, 2004
- Drug development for neglected diseases: a deficient market and a public-health policy failureThe Lancet, 2002
- Relation between burden of disease and randomised evidence in sub-Saharan Africa: survey of researchBMJ, 2002